Resource for Clinical Studies of AKI (Clinical Research/Genomics/Biorepository)

AKI 临床研究资源（临床研究/基因组学/生物样本库）

• 批准号: 9334184
• 负责人: Ravindra L. Mehta
• 金额: $ 30.36万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9334184
• 关键词: Acute Renal Failure with Renal Papillary Necrosis; Adult; Basic Science; Biological; Biological Assay; Biological Markers; Cessation of life; Childhood; Chronic Kidney Failure; Clinical; Clinical Data; Clinical Investigator; Clinical Research; Coupled; DNA; Databases; Diagnosis; Disease; Functional disorder; Genetic Determinism; Genomics; Goals; Hospitalization; Human; Human Resources; Individual; Injury; Instruction; International; Investigation; Kidney; Knowledge; Lead; Link; Natural History; Online Systems; Outcome; Pathway interactions; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Phenotype; Prospective Studies; Protocols documentation; Publications; Registries; Renal function; Research; Research Personnel; Resources; Risk; Sampling; System; Translational Research; Translations; base; biobank; clinical investigation; clinical phenotype; data acquisition; data management; design; flexibility; follow-up; genomic predictors; improved outcome; insight; international center; longitudinal course; novel; repository; research study; tool

PROJECT SUMMARY (See instructions): Clinical and translational research in acute kidney injury (AKI) requires well designed prospective studies as well as access to well characterized patients with longitudinal follow up coupled with biological samples enabling investigators to probe the underlying mechanisms and pathways contributing to outcomes. The specific aims of the Resource for Clinical Studies of AKI (Core A) are to 1) provide core resources to support the design and conduct of clinical research In AKI, 2) provide a genomics resource to perform systematic genomic analyses and allow correlation with clinical phenotypic information, and 3) provide a biological sample repository linked to the clinical and genomics database for the characterization of patients for our investigator base. This core will specifically provide investigators access to patients with AKI through an established international network of collaborating investigators who are contributing to an ongoing registry of AKI in the ICU setting currently with over 1000 patients, access to biological samples including DNA from patients and healthy controls and protocols and tools for quantitative assessment of changes in kidney function. Since its inception the Core has been successful in supporting investigators for clinical and translational research. The Core has established a robust data management system and database of patients with AKI that Is flexible In accommodating the research objectives of individual investigators and collaborating centers; currently supporting 5 large multicenter projects including the AKI registry and an international prospective study for the genomics of drug-induced kidney injury. The genomics resource has facilitated the investigation of genetic determinants (both risk and outcome) of AKI, and identified novel genomic predictors of the longitudinal course in AKI. Over 14,000 biomarker assays incorporating more than 20 analytes have been performed to support both pediatric and adult AKI research. A biological sample repository has been established and has >2000 sequential samples from well-characterized patients with and without AKI. The Core has supported 143 projects for 52 investigators (including 4 pilot recipients and 45 non-core personnel), resulting in 57 publications. These rich resources will continue to enable interdisciplinary clinical investigation in AKI to advance our understanding of the natural history, pathophysiology and treatment of human AKI. Core A in conjunction with existing resources at UAB and UCSD and other cores within the O'Brien center will accelerate the translation of new investigative insights towards improving outcomes for patients with AKI.

项目摘要（参见说明）：急性肾损伤（AKI）的临床和转化研究需要精心设计的前瞻性研究，以及对特征明确的患者进行纵向随访，并结合生物样本，使研究人员能够探究导致结果的潜在机制和途径。 AKI 临床研究资源（核心 A）的具体目标是 1) 提供核心资源来支持 AKI 临床研究的设计和实施，2) 提供基因组学资源以执行系统基因组分析并允许与临床表型信息相关，3) 提供与临床和基因组学数据库链接的生物样本存储库，用于为我们的研究者基础描述患者的特征。该核心将专门为研究人员提供通过已建立的国际合作研究人员网络接触 AKI 患者的机会，这些合作研究人员正在为目前 ICU 环境中超过 1000 名患者的 AKI 持续登记做出贡献，获得生物样本，包括来自患者和健康对照的 DNA，以及用于定量评估肾功能变化的方案和工具。自成立以来，Core 已成功支持研究者进行临床和转化研究。核心建立了一个强大的数据管理系统和 AKI 患者数据库，可以灵活地适应个体研究者和合作中心的研究目标；目前支持 5 个大型多中心项目，包括 AKI 登记和药物性肾损伤基因组学国际前瞻性研究。基因组学资源促进了 AKI 遗传决定因素（风险和结果）的研究，并确定了 AKI 纵向病程的新型基因组预测因子。已进行超过 14,000 项包含 20 多种分析物的生物标志物测定，以支持儿科和成人 AKI 研究。生物样本库已经建立，拥有超过 2000 个来自患有和不患有 AKI 的明确特征患者的连续样本。核心支持了 52 名研究人员（包括 4 名试点接受者和 45 名非核心人员）的 143 个项目，发表了 57 篇出版物。这些丰富的资源将继续促进 AKI 的跨学科临床研究，以增进我们对人类 AKI 的自然史、病理生理学和治疗的理解。核心 A 与 UAB 和 UCSD 的现有资源以及 O'Brien 中心的其他核心相结合，将加速新的研究见解的转化，以改善 AKI 患者的治疗结果。